Rita Quelhas da Costa1,2, M Elena Aguirre-Alastuey1,3, David A Isenberg1, Amanda M Saracino1. 1. Department of Rheumatology, University College London Hospital, University College London, London, United Kingdom. 2. Department of Internal Medicine, Centro Hospitalar do Porto, Porto, Portugal. 3. Department of Internal Medicine, Compleio Asistencial Universitario de León, León, Spain.
Abstract
Importance: Cutaneous lupus erythematosus (CLE) can be severe and treatment resistant. B-cell depletion therapy (BCDT) with rituximab is well recognized in organ involvement in systemic lupus erythematosus (SLE), but its efficacy in cutaneous manifestations is less well established. Objective: To evaluate the outcomes of BCDT in CLE and its clinical subtypes in the setting of associated SLE. Design, Setting, and Participants: This single-center, retrospective, cohort study was performed at the adult tertiary referral Rheumatology Department of University College London Hospital, London, United Kingdom, from January 1, 2000, through March 31, 2016, with 12-month follow-up completed on March 31, 2017. Adult patients with carefully classified CLE and mucocutaneous British Isles Lupus Assessment Group (BILAG) grade A or B who were treated with rituximab BCDT were selected from a prospective database of 709 patients with SLE. Data were analyzed from April through December 2017. Main Outcomes and Measures: Clinical response was examined at 6 and 12 months after treatment for CLE and its subtypes acute CLE (ACLE), subacute CLE (SCLE), chronic CLE (CCLE), and nonspecific LE (NSLE). A complete response was defined as achieving BILAG grade D; partial response, BILAG grade C; stable disease, no change; and disease flare, change from BILAG grade C or D to grade A or B. Results: A total of 50 patients with SLE were eligible for inclusion; mean (SD) age at diagnosis was 26.9 (12.1) years, and 49 (98%) were women. Twenty-one patients had ACLE; 6, SCLE; 10, CCLE; and 11, NSLE (including 2 with concurrent ACLE and CCLE). Overall, at 6 months, 38 patients (76%) improved their mucocutaneous BILAG grade A or B status, including 20 (40%) with a complete response. At 12 months, 28 of 46 patients (61%) maintained this response, including 24 (52%) with a complete response. Two of 6 patients (33%) with SCLE showed a complete response at 6 and 12 months. Five of 12 patients (42%) with CCLE showed a complete response at 6 months, and 5 of 11 (45%), at 12 months. Fifteen patients (30%) required further rituximab therapy within 12 months for cutaneous involvement. Conclusions and Relevance: B-cell depletion therapy using rituximab appears effective in patients with SLE and severe active CLE; however, outcomes are variable in those with SCLE and CCLE subtypes.
Importance: Cutaneous lupus erythematosus (CLE) can be severe and treatment resistant. B-cell depletion therapy (BCDT) with rituximab is well recognized in organ involvement in systemic lupus erythematosus (SLE), but its efficacy in cutaneous manifestations is less well established. Objective: To evaluate the outcomes of BCDT in CLE and its clinical subtypes in the setting of associated SLE. Design, Setting, and Participants: This single-center, retrospective, cohort study was performed at the adult tertiary referral Rheumatology Department of University College London Hospital, London, United Kingdom, from January 1, 2000, through March 31, 2016, with 12-month follow-up completed on March 31, 2017. Adult patients with carefully classified CLE and mucocutaneous British Isles Lupus Assessment Group (BILAG) grade A or B who were treated with rituximab BCDT were selected from a prospective database of 709 patients with SLE. Data were analyzed from April through December 2017. Main Outcomes and Measures: Clinical response was examined at 6 and 12 months after treatment for CLE and its subtypes acute CLE (ACLE), subacute CLE (SCLE), chronic CLE (CCLE), and nonspecific LE (NSLE). A complete response was defined as achieving BILAG grade D; partial response, BILAG grade C; stable disease, no change; and disease flare, change from BILAG grade C or D to grade A or B. Results: A total of 50 patients with SLE were eligible for inclusion; mean (SD) age at diagnosis was 26.9 (12.1) years, and 49 (98%) were women. Twenty-one patients had ACLE; 6, SCLE; 10, CCLE; and 11, NSLE (including 2 with concurrent ACLE and CCLE). Overall, at 6 months, 38 patients (76%) improved their mucocutaneous BILAG grade A or B status, including 20 (40%) with a complete response. At 12 months, 28 of 46 patients (61%) maintained this response, including 24 (52%) with a complete response. Two of 6 patients (33%) with SCLE showed a complete response at 6 and 12 months. Five of 12 patients (42%) with CCLE showed a complete response at 6 months, and 5 of 11 (45%), at 12 months. Fifteen patients (30%) required further rituximab therapy within 12 months for cutaneous involvement. Conclusions and Relevance: B-cell depletion therapy using rituximab appears effective in patients with SLE and severe active CLE; however, outcomes are variable in those with SCLE and CCLE subtypes.
Authors: M Witt; M Grunke; F Proft; M Baeuerle; M Aringer; G Burmester; G Chehab; C Fiehn; R Fischer-Betz; M Fleck; K Freivogel; M Haubitz; I Kötter; S Lovric; C Metzler; A Rubberth-Roth; A Schwarting; C Specker; H-P Tony; L Unger; S Wassenberg; T Dörner; H Schulze-Koops Journal: Lupus Date: 2013-10 Impact factor: 2.911
Authors: Edward M Vital; Miriam Wittmann; Sara Edward; Md Yuzaiful Md Yusof; Helen MacIver; Colin T Pease; M Goodfield; Paul Emery Journal: Arthritis Rheumatol Date: 2015-06 Impact factor: 10.995
Authors: A Fernández-Nebro; J L Marenco de la Fuente; L Carreño; M Galindo Izquierdo; E Tomero; I Rúa-Figueroa; B E Hernández-Cruz; J Narváez; E Ucar; A Olivé; A Zea; M Fernández-Castro; E Raya-Álvarez; J M Pego-Reigosa; M Freire; V M Martínez-Taboada; J Pérez-Venegas; A I Sánchez-Atrio; I Villa-Blanco; S Manrique-Arija; F J López-Longo; P E Carreira; R Martínez-Pérez; R García-Vicuña Journal: Lupus Date: 2012-07-11 Impact factor: 2.911
Authors: Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Tim Y-T Lu; Kristine P Ng; Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael Ehrenstein; David A Isenberg Journal: Arthritis Rheum Date: 2009-04-15
Authors: Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta Journal: Arthritis Rheum Date: 2010-01
Authors: Md Yuzaiful Md Yusof; Daniel Shaw; Yasser M El-Sherbiny; Emma Dunn; Andy C Rawstron; Paul Emery; Edward M Vital Journal: Ann Rheum Dis Date: 2017-07-06 Impact factor: 19.103
Authors: Lisa Abernathy-Close; Stephanie Lazar; Jasmine Stannard; Lam C Tsoi; Sean Eddy; Syed M Rizvi; Christine M Yee; Emily M Myers; Rajaie Namas; Lori Lowe; Tamra J Reed; Fei Wen; Johann E Gudjonsson; J Michelle Kahlenberg; Celine C Berthier Journal: Front Immunol Date: 2021-11-19 Impact factor: 7.561
Authors: Alice Verdelli; Alberto Corrà; Elena Biancamaria Mariotti; Cristina Aimo; Valentina Ruffo di Calabria; Walter Volpi; Lavinia Quintarelli; Marzia Caproni Journal: Front Med (Lausanne) Date: 2022-09-23